ABSTRACT Hyperuricemia demonstrates synergistic interactions in the progression of hyperlipidemia and hyperglycemia. There is a pressing demand to explore natural products with negligible adverse effects for the prevention and regulation of hyperuricemia, particularly when combined with hyperglycemia and hyperlipidemia. Ampelopsis grossedentata has been traditionally employed as a functional food throughout an extensive historical duration. Nevertheless, the bioactive compounds that contribute to its hypoglycemic, hypolipidemic, and hypouricemic effects, as well as the molecular mechanisms involved, have not yet been completely clarified. This study initially conducted in vitro assays to evaluate the inhibitory activity of A. grossedentata towards α‐glucosidase, pancreatic lipase, and xanthine oxidase. The results revealed that the A. grossedentata extract exhibited substantial inhibitory activities against these enzyme targets. Subsequently, the four most promising active compounds (quercetin, myricetrin, dihydromyricetin and taxifolin) were screened and characterized by a bioaffinity ultrafiltration method combined with LC‐MS/MS analysis. Further validation of these bioactive compounds was achieved through molecular docking studies. Additionally, an interaction network was established to elucidate the mechanisms of action between the candidate constituents and their respective targets. The results indicate that A. grossedentata holds great promise as a potential natural therapeutic functional food for managing diabetes, overweight, and hyperuricemia in the foreseeable future.
Mao et al. (Thu,) studied this question.